Article: Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts
Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.
- Assessing commercial viability
- Developing clinical trial design and evidence-generation strategy
- Planning for launch preparedness
Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.
Leaping the Next Hurdle in CAR T-Cell Therapies
While chimeric antigen receptor (CAR) T-cell therapy has demonstrated its ability to produce responses in refractory tumors, many challenges remain with the therapies. Precision’s Phil Cyr discusses some of these challenges as well as questions and research that remain to be answered.
Read the full article here!
On-Demand: State of the Union for Advanced Medicines
Regenerative medicines are evolving at breakneck speed—and every advance has far-reaching implications. To be effective in CGTx development, you also need to understand the current investment landscape, new and exciting technologies, and the latest progress in drug development, manufacturing, regulatory, and reimbursement.
Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss how to be effective in CGTx development. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Phil Cyr (EVP, Precision Value & Health), David Greenwald (VP of Business Development, Deerfield Management), Rajul Jain (Managing Director, Vida Ventures), Joseph La Barge (CEO, Apertura Gene Therapy), and Adrian Woolfson (Executive Chairman, President & Co-Founder, Replay Bio).
Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics
BETHESDA, MD — Nov. 3, 2022 — Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) initiative which improved the accuracy and speed of identifying cancer mutations in solid tumors, allowing researchers and manufacturers to develop patient-specific diagnostics for improved clinical outcomes.
On-Demand: What’s Next for Cell and Gene Therapies in 2023 and Beyond
At this years Meeting on the Mesa’s conference, Anshul Mangal: President (Precision ADVANCE and Project Farma) sat down with leading industry experts to discuss the future of cell and gene therapies.